United States

McKesson Corp (MCK)

MCK on New York Consolidated

20 Sep 2017
Change (% chg)

$2.11 (+1.42%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


McKesson Corporation (McKesson) is engaged in delivering pharmaceuticals, medical supplies and healthcare information technology. The Company operates through two segments: McKesson Distribution Solutions and Technology Solutions. The McKesson Distribution Solutions segment distributes drugs and equipment, and health and beauty... (more)


Beta: 1.16
Market Cap(Mil.): $31,196.36
Shares Outstanding(Mil.): 210.26
Dividend: 0.34
Yield (%): 0.92


  Industry Sector
P/E (TTM): -- 21.77 16.25
EPS (TTM): -- -- --
ROI: -- 11.95 14.87
ROE: -- 13.64 13.89

BRIEF-Truveris secures $25 mln in new funding round led by McKesson Ventures

* Truveris has secured $25 million in a new round of funding led by McKesson Ventures Source text for Eikon:

Sep 06 2017

BRIEF-James Beer, EVP, CFO of Mckesson Corporation, joins Alaska Air board of directors

* James Beer, EVP, CFO of Mckesson Corporation, joins Alaska Air Group board of directors

Aug 03 2017

BRIEF-Allscripts to acquire Mckesson’s Enterprise Information Solutions business

* Allscripts to acquire Mckesson’s enterprise information solutions business

Aug 03 2017

Drug pricing pressure weighs on AmerisourceBergen forecast

Drug distributor AmerisourceBergen Corp cut its fiscal 2017 revenue growth forecast on Thursday and warned investors of the continuing fall in generic drug prices, adding that the pace of branded drug price increases could slow further.

Aug 03 2017

UPDATE 3-Drug pricing pressure weighs on AmerisourceBergen forecast

* Shares fall as much as 11 pct; rivals also slump (Adds conf call details, analysts' comments, updates shares)

Aug 03 2017

McKesson profit dragged by tepid growth in branded drug prices

McKesson Corp , the biggest U.S. drug distributor, posted a much lower-than-expected quarterly profit, hurt by the lingering effects of a slowdown in the pace of price increases for branded drugs, sending its shares down as much as 6 percent.

Jul 27 2017

UPDATE 3-McKesson profit dragged by tepid growth in branded drug prices

* Raises fiscal 2018 earnings forecast to $11.80-$12.50/share

Jul 27 2017

BRIEF-Mckesson reports fiscal 2018 first-quarter results

* Q1 GAAP earnings per share $1.44 from continuing operations

Jul 27 2017

McKesson quarterly profit falls 43 pct

July 27 Drug wholesaler McKesson Corp reported a 43 percent fall in quarterly profit due to slower increase in drug prices and intensifying competition.

Jul 27 2017

McKesson shareholders vote against executive pay structure

McKesson Corp's shareholders voted against the company's executive pay policy, following a campaign that criticized the drug wholesaler for its role in the U.S. opioid drug epidemic.

Jul 26 2017

Earnings vs. Estimates